KRAS and familial pancreatic carcinoma: Taken together, this study demonstrated the anti-tumor action of K-Ras, PI3K-activated MSC CM, and PKA-activated PBMC CM, indicating the possibility of unconventional proteome-based therapy for pancreatic cancer.